SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Summary
This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of improvement or did not respond to previous treatment. Monoclonal antibodies, such as SGN-30, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride, vinorelbine tartrate, and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody SGN-30 together with combination chemotherapy may kill more cancer cells and shrink tumors.
Timeline
- Start
- 2006-04
- Primary completion
- 2008-09
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGN-30 | Monoclonal antibody | 12 mg/kg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 10 mg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 15 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 800 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Vinorelbine | Small molecule | 15 mg/m2 | Intravenous |
| Background | Vinorelbine | Small molecule | 20 mg/m2 | Intravenous |